New Endometrial Targets Beyond HER2

Interest in endometrial cancer extends well beyond HER2, and the faculty review a growing pipeline of antibody drug conjugates directed at additional targets. Discussion includes why TROPE2 and other emerging targets are generating enthusiasm, particularly because they may broaden treatment options for patients who do not meet narrower biomarker criteria associated with some currently available therapies. At the same time, the conversation remains highly practical, with attention to how different payloads and toxicity profiles may affect adoption in routine care. Gastrointestinal adverse events, stomatitis, pulmonary concerns, and supportive care requirements all factor into how clinicians may view the next wave of therapies. The panel also considers whether efficacy might differ across levels of target expression and histologic subtypes, reinforcing the need for more refined biomarker strategies as development moves forward. Overall, the evolving pipeline suggests meaningful opportunity in recurrent endometrial cancer, but also a need for caution as clinicians interpret early data and prepare for more complex treatment choices.